Eosinophilic Gastritis
- Home
- Solutions
- By Diseases
- Gastric Diseases
- Eosinophilic Gastritis
Eosinophilic gastritis is an uncommon disorder in children and adults with eosinophilic infiltration, which can be classified as eosinophilic gastrointestinal disorders (EGIDs). Protheragen is a research service provider that provides one-stop research and development services for preclinical drug efficacy and safety testing for eosinophilic gastritis using in vitro and in vivo methods.
Eosinophilic gastritis is one of the various chronic inflammatory disorders with eosinophilic infiltration in specific parts of the digestive tract. Earlier records from a database of studies show the prevalence of eosinophilic gastritis to be 6.2 per 100,000 people. Moreover, the prevalence of eosinophilic gastritis progressively decreased with increasing age, being the most pronounced among individuals below five years of age for both boys and girls. Eosinophilic gastritis manifestations are heterogeneous and vary according to the region of eosinophilic infiltration, and the layers of the wall involved.
Fig.1 Mechanisms of action for the most frequently tested monoclonal antibodies in EGIDs. (Marasco, G., et al., 2023)The primary cause for these eosinophilic gastrointestinal diseases which also have eosinophilic esophagitis and enteritis as subtypes is immunological hypersensitivity to food antigens. Gastrointestinal eosinophilia results from the combination of innate and adaptive immune systems stimulated by type 2 immune responses, including but not limited to, the production of interleukin (IL)-5 and IL-13 by T helper type 2 cells, and eotaxin production by epithelial cells.
Fig.2 Pathology of eosinophilic gastritis. (Chen, P. H., et al., 2021)
| Drug Names | Mechanism of Action | Targets | Research Phase |
| Prednisolone | Inhibit the growth factors IL-3, IL-5, and GM-CSF that stimulate eosinophils. | GR | Approved |
| Cromolyn | Block the release of histamine, leukotrienes, and substances that attract eosinophils. | / | Approved |
| AK002 | Reduce eosinophils and block mast cell activity. | Siglec-8 | Phase III |
| Benralizumab | Remove eosinophils from gastric tissue. | IL5Rα | Phase II |
| CC-93538 | Identify IL-13 and prevent its binding to both IL-13 receptor-specific subtypes. | IL-13 | Phase III |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Comprising skilled professionals who possess better understanding and experience in the area of gastroenterology and drug development ensuring that your project receives strong support. Tailored specifically to support the development of potential therapeutics for challenging conditions, including diagnostic, therapeutic, and disease model development services, our services offer comprehensive assistance.
Comprehensive services coverage of animal model development, including model design, validation, and characterization, ensures that the developed models are strong, reliable, and applicable in preclinical pharmaceutical testing and research. Whether you need a mouse, rat, or other animal model, we can tailor our services.
Oral ovalbumin (OVA) allergen or intra-peritoneal injections of peanut protein extract (PPE) induced eosinophilic gastritis in animals.
These models involve overexpression of the IL-5 gene which causes an increase in eosinophils and simulates the features of eosinophilic gastritis.
From pharmacokinetic studies to drug safety assessments, Protheragen provides accurate and expert support for eosinophilic gastritis drug development. We ensure effective assistance by customizing the specific preclinical services according to the requirements of the client's project. If you need further details on the services we provide, please reach out to us.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.